03Apr/14

Monoclonal Antibodies Market in Gastric and Esophageal Cancers to 2019 … – PR Newswire (press release)

April 3, 2014Antibodiesadmin

Monoclonal Antibodies Market in Gastric and Esophageal Cancers to 2019 …
PR Newswire (press release)
GBI Research has released the pharma report “Monoclonal Antibodies Market in Gastric and Esophageal Cancers to 2019 – Crowded Late-Stage Pipelines and Favorable Market Conditions Encourage Robust Growth” Gastric and esophageal cancers are two …
Monoclonal Antibodies Market in Colorectal Cancer to 2019 – Favorable Pricing …Virtual Press Office (press release)

all 2 news articles »

03Apr/14

Monoclonal Antibodies Market in Colorectal Cancer to 2019 – Favorable Pricing … – PR Newswire (press release)

April 3, 2014Antibodiesadmin

Monoclonal Antibodies Market in Colorectal Cancer to 2019 – Favorable Pricing …
PR Newswire (press release)
GBI Research, has released the pharma report “Monoclonal Antibodies Market in Colorectal Cancer to 2019 – Favorable Pricing Policy in the US and Rising Prevalence in Europe and Japan Ensures Market Growth”. There are currently three monoclonal …

and more »

03Apr/14

Monoclonal Antibodies Market in Colorectal Cancer to 2019 – Favorable Pricing … – Virtual Press Office (press release)

April 3, 2014Antibodiesadmin

Monoclonal Antibodies Market in Colorectal Cancer to 2019 – Favorable Pricing …
Virtual Press Office (press release)
GBI Research, has released the pharma report “Monoclonal Antibodies Market in Colorectal Cancer to 2019 – Favorable Pricing Policy in the US and Rising Prevalence in Europe and Japan Ensures Market Growth”. There are currently three monoclonal …

and more »

03Apr/14

Mantle Cell Lymphoma — Still More Questions Than Answers – Medscape

April 3, 2014Monoclonal Anti-CD20 Antibodiesadmin

Medscape

Mantle Cell Lymphoma — Still More Questions Than Answers
Medscape
Expression of Ki-67, a nuclear protein involved in cell proliferation regulation, has been demonstrated to be the most powerful single prognostic factor for overall survival, including in patients treated with rituximab-containing regimens. “If the Ki …

03Apr/14

Xencor Inc.: Current Biotech Uncertainty Is An Opportunity – Seeking Alpha

April 3, 2014Monoclonal Anti-CD20 Antibodiesadmin

Xencor Inc.: Current Biotech Uncertainty Is An OpportunitySeeking AlphaPrevious drugs such as Rituximab or Rituxan (Biogen (BIIB) and Roche/Genentech) have also targeted B-cells in RA but have safety issues due to excessive B-cell depletion. However, i…

03Apr/14

Experts praise drug trial for building a realistic study population – Oncology Nurse Advisor

April 3, 2014Monoclonal Anti-CD20 Antibodiesadmin

Experts praise drug trial for building a realistic study populationOncology Nurse AdvisorResearchers compared the benefits of obinutuzumab with that of another antibody rituximab, which also attacks CD20. Both drugs were combined with the chemotherapy …

03Apr/14

Competitor Analysis: Biosimilar and Biosuperior Therapeutic Antibodies – SYS-CON Media (press release)

April 3, 2014Antibodiesadmin

Competitor Analysis: Biosimilar and Biosuperior Therapeutic AntibodiesSYS-CON Media (press release)The present Competitive Intelligence Report about Biosimilar and Biosuperior Therapeutic Antibodies 2014 provides a competitor evaluation in the field of…

02Apr/14

Patrys produces IgM antibodies using plants – Australian Life Scientist

April 2, 2014Antibodiesadmin

Patrys produces IgM antibodies using plantsAustralian Life ScientistPatrys (ASX:PAB) has developed a method of producing anticancer antibody PAT-SM6 using a plant-based manufacturing system. Details of a plant-based alternative production system for Im…

02Apr/14

Biologics Do Not Raise Cancer Risk for RA Patients – American News Report

April 2, 2014Monoclonal Anti-CD20 Antibodiesadmin

American News ReportBiologics Do Not Raise Cancer Risk for RA PatientsAmerican News ReportBiologics (such as rituximab and anti-TNF) are made from genetically engineered proteins derived from human genes. Like DMARDS, they inhibit parts of the immune s…

02Apr/14

Patents, biosimilars and trademarks – another triangle? – IAM (registration) (blog)

April 2, 2014Monoclonal Anti-CD20 Antibodiesadmin

Patents, biosimilars and trademarks – another triangle?
IAM (registration) (blog)
Although Roche was taking steps to use Emcure Pharmaceuticals in India “to produce its innovative biologics in India” and to reduce the price for cancer drugs trastuzumab (Herceptin) and rituximab (MabThera), in a surprising but strategic move, Roche …

Category Archives: Antibodies